bli-1301

BLI-1301 is a natural anti-cancer ingredient extracted from a special fungus using a patented process developed by Yukiguni Maitake Co. Ltd., Japan. It is classified as an immunomodulator and small molecule drug. The primary indication for BLI-1301 is the treatment of myelodysplastic syndromes (MDS), a group of rare hematological cancers characterized by ineffective hematopoiesis and increased risk of infection due to cytopenias. Animal and human studies have shown that oral administration of BLI-1301 can enhance the immune system, repair hematopoietic stem cells, and potentially reduce infection risk in MDS patients. The drug has also been investigated for breast cancer[6][2][1].

Other names

Maitake D-fractionGrifola frondosa extractbeta-glucan from Grifola frondosa